Tilray Medical announced the final results of a new scientific study its team has supported titled, "Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)."
This randomized, placebo-controlled trial aimed to test the effectiveness of an oral cannabis extract in adults suffering from CINV despite standard anti-nausea treatments. Participants received capsules containing 2.5 mg of THC and 2.5 mg of CBD or a placebo, taken three times daily for six days.
From 2016 to 2022, 147 participants were recruited. The study found that the cannabis extract significantly improved the rate of complete response—meaning no vomiting or use of additional medications—from 8% with placebo to 24% with THC: CBD. Other benefits included reduced nausea and fewer daily vomits. However, some side effects were noted, such as sedation (18% vs. 7%), dizziness (10% vs. 0%), and transient anxiety (4% vs. 1%).
“These findings are encouraging for cancer patients undergoing chemotherapy. This study is a crucial step in improving patient care and quality of life," said Denise Faltischek, Chief Strategy Officer, and Head of International at Tilray Brands. "Our involvement in this study underscores our commitment to advancing medical research. The positive outcomes highlight the potential of cannabinoids for managing CINV."
